Key Highlights

• Piramal says its Digwal factory has undergone 415 inspections since 2012, including 49 from the FDA, with zero serious violations.

• Dr. Reddy's underwent a surprise inspection two weeks after the tariff on generics was declared.

• One lifesaving drug travels about 8,000 miles by air from Digwal to a Piramal facility in Riverview, Michigan.

• China became the dominant maker of active drug ingredients from the 1990s, and India is now trying to reclaim that capability.

A History of Quality Concerns

For years, heavy reliance on Indian factories carried a drawback in quality. A series of scandals beginning in the early 2000s tarnished the industry's reputation. The most notorious offender, Ranbaxy, sold subpar drugs and lied to the US Food and Drug Administration about its processes before going under more than a decade ago. A book about the scandal has become required reading for many industry managers. According to its epilogue, as recently as 2019 the FDA still announced Indian factory inspections days in advance, giving operators time to conceal poor practices.

That is no longer the case, at least among big manufacturers. Dr. Reddy's underwent a surprise inspection two weeks after Trump declared a tariff on generics. Piramal said its factory in Digwal, three hours west of Hyderabad, has undergone 415 inspections since it was built in 2012, including 49 from the FDA, with zero serious violations detected.

Generics and Contract Manufacturing

Piramal makes generics, but an even larger part of its business is contract manufacturing for clients that hold drug patents. Keeping smaller factories in the United States makes it easier for some of those customers to keep tabs on production.

Supply Chains That Cross Borders

That geographic spread points to another problem with trying to make all pharmaceuticals locally. Modern drug supply chains do not divide neatly into products made in America and products imported from elsewhere. One sealed barrel among thousands in Piramal's main Digwal storeroom had been made in India, shipped to Singapore and back, and carried the brand of a Japanese company with an American address.

Another drug, which the Piramal chief executive described only as a lifesaving medicine for central nervous system conditions, begins its journey in Digwal and then travels 8,000 miles by air to the company's facility in Riverview, Michigan. Riverview, a quiet suburb of Detroit with broad lawns and white steeples, is a far cry from Digwal, where nearby villages still draw water from stone-lined wells. Specialized machines in Piramal's Indian and American labs collaborate to turn the medicine into its final form.

Why Facilities Are Paired

There are good reasons to pair facilities in India with plants in the destination market, the Piramal chief executive said. Some drugs require especially dangerous chemicals, including some controlled by the Drug Enforcement Administration. Others, such as sevoflurane, a generic anesthetic Piramal makes in both India and the United States, must remain available even if international supply chains break down completely.

What Problem Is the Tariff Meant to Solve?

The prospect of a tariff on imported generics raises a more fundamental question, in the executive's view. Is the aim to bring pharmaceutical jobs back to American workers, or to safeguard supplies of vital medicines? He put it directly: "So what problem are you trying to solve?"

The China Dependency

Even as Indian firms contend with the Trump administration's push to reduce its dependence on India, they face their own reliance on another country for a critical part of the supply chain. Starting in the 1990s, China became the world's dominant manufacturer of the active ingredients most drugs require. India is now trying to reclaim that capability.

According to the secretary general of the Indian Pharmaceutical Alliance, this creates an opportunity for the United States and India to work together rather than pull their pharmaceutical industries apart. Without cooperation with the United States, he said, India would depend on China for ingredients. He added that it makes sense for American buyers to stockpile from India rather than manufacture in the United States at six, seven or eight times the price.

Points of Reference

The inspection record at Digwal, the 8,000-mile route between Digwal and Riverview, the pairing of facilities across countries and China's share of active ingredient production are the details that frame the debate over where generics are made.